Selected Reading
- Berglund U, Wallen tin L: Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine. Atherosclerosis 59: 241, 1986
- Cassidy LJ, Schuster BG, Halparin LS: Probable ticlopidine-induced cholestatic hepatitis. Ann Pharmacother 29: 30, 1995
- Grimm IS, Litynski JJ: Severe cholestasis associated with ticlopidine. Am J Gastroenterol 89: 279, 1994
- Hass WK et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321: 501, 1989
- Naschitz JE et al: Ticlopidine-induced prolonged cholestasis (letter). Clin Toxicol 33: 379, 1995
- Norredam K: Chlorpromazine jaundice of long duration. Acta Med Scand 174: 163, 1963
- Nurhussein MA: Ticlopidine-induced prolonged cholestasis (letter). J Am Geriatr Soc 41: 1371, 1993
- Seidel D et al: A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins. J Clin Invest 49: 2396, 1970
- Stolzer BL et al: Postarsenical obstructive jaundice complicated by xanthomatosis and diabetes mellitus. Am J Med 9: 124, 1950
- Yoder JD, Algozzine GJ, Hill GW: More ticlopidine-induced cholestatic jaundice (letter). Am J Hosp Pharm 51: 1821, 1994